Retro Biosciences

Retro Biosciences is a biotech company that is positioning itself to address the growing gap between healthspan and lifespan. Its mission is to “extend human lifespan by 10 years” by developing “therapies that meaningfully reverse age-related diseases.” Retro Biosciences uses cellular reprogramming and other biological therapies to attempt to reverse aging and treat diseases at a cellular level. Its advanced biotech expertise and partnership with OpenAI enable Retro Biosciences to tackle multiple therapeutic areas in parallel and pursue an aggressive development timeline, with its first human clinical trial having begun in December 2025.